Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx1-PCAQ
- Development stage
- Unknown
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx1-PCAQ is a viral-vectored cancer vaccine candidate designed for the treatment of prostate cancer. It utilizes the ChAdOx1 adenoviral vector platform to deliver and express four prostate cancer-associated antigens—prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six transmembrane epithelial antigen of the prostate 1 (STEAP1), and oncofetal trophoblast glycoprotein 5T4. Upon administration, the vaccine expresses these peptides, which may elicit both humoral and cellular immune responses against prostate cancer cells expressing these antigens[1]. The approach aims to stimulate an anti-tumor immune response by targeting multiple tumor-associated antigens.
- Other names
- ChAdOx1-PSA/PAP/STEAP1/5T4 prostate cancer vaccine
02
Targets
PAP (Prostatic acid phosphatase)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)TPBG (Trophoblast glycoprotein)PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on ChAdOx1-PCAQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx1-PCAQ.